MHRA: Casgevy Approval for Children as Young as 5 in UK

• The MHRA has extended the UK authorization for Casgevy (exagamglogene autotemcel) to include children aged five and over.
• This gene-editing treatment targets severe sickle-cell disease and transfusion-dependent β-thalassemia.
• Previously, Casgevy was only approved for patients aged 12 and older in the UK.
• Casgevy works by editing faulty genes in bone marrow stem cells to produce functioning haemoglobin.
• Vertex Pharmaceuticals (Europe) Ltd. received the marketing authorisation extension on October 29, 2026.

Lawyers advising pharmaceutical companies or healthcare providers in the UK should note the expanded market authorization for Casgevy, which now includes children aged five and over.

The Medicines and Healthcare products Regulatory Agency (MHRA) has significantly broadened the scope of a pioneering gene-editing therapy, Casgevy (exagamglogene autotemcel), in the UK. This pivotal MHRA Casgevy approval children UK now permits the treatment of children as young as five years old who suffer from severe sickle-cell disease and transfusion-dependent β-thalassemia. This marks a notable expansion from its previous authorization, which limited eligibility to patients aged 12 and above.

This extension of the UK approval for exagamglogene autotemcel means that a younger demographic of patients grappling with these debilitating inherited blood disorders can now access this innovative therapeutic option. The decision by the MHRA underscores a commitment to providing advanced medical interventions to those most in need, particularly where existing treatments may be insufficient or burdensome.

Casgevy operates by directly modifying a faulty gene within a patient's bone marrow stem cells, enabling the body to produce functional haemoglobin. This process begins with the collection of stem cells from the patient, followed by their genetic editing in a laboratory setting. Once modified, these cells are then re-infused into the patient after a preparatory conditioning treatment.

Both severe sickle cell disease and β-thalassemia are rooted in genetic errors affecting haemoglobin, the protein responsible for oxygen transport in red blood cells. Sickle cell disease manifests through severe pain crises, serious infections, and anaemia, while β-thalassemia primarily leads to severe anaemia, often necessitating blood transfusions every three to five weeks, alongside lifelong medication and injections. While offering significant promise, the MHRA gene editing treatment is associated with potential side effects, including nausea, fatigue, fever, and an increased risk of infection. Patients also typically require a hospital stay post-infusion to allow the treated cells to establish themselves and begin producing healthy red blood cells.

The marketing authorisation extension for Casgevy was formally granted to Vertex Pharmaceuticals (Europe) Ltd. on October 29, 2026. This regulatory action by the MHRA, an executive agency of the Department of Health and Social Care, reflects its mandate to ensure the safety and efficacy of all medicines and medical devices within the UK. The agency’s rigorous assessment underpins such approvals, balancing potential risks against the demonstrated benefits of new treatments.

With approximately 15,000 individuals in the UK affected by sickle cell disorder, the expanded Casgevy sickle cell children approval holds substantial implications for patient care and public health. Lawyers advising pharmaceutical companies or healthcare providers in the UK should note the expanded market authorization for Casgevy, which now includes children aged five and over. This development has implications for product liability, patient consent protocols for a younger demographic, and regulatory compliance for the administration of this gene-editing treatment. Compliance officers in healthcare settings must update treatment eligibility criteria and patient information regarding this expanded therapeutic option. The MHRA will continue to monitor the safety and effectiveness of Casgevy, as is standard practice for all approved medicines.

Lawyers advising pharmaceutical companies or healthcare providers in the UK should note the expanded market authorization for Casgevy, which now includes children aged five and over. This development has implications for product liability, patient consent protocols for a younger demographic, and regulatory compliance for the administration of this gene-editing treatment. Compliance officers in healthcare settings must update treatment eligibility criteria and patient information regarding this expanded therapeutic option.

Source: Original reporting via GOV.UK